

Amy J Davidoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1505313/publications.pdf>

Version: 2024-02-01

136
papers

3,171
citations

172457

29
h-index

175258

52
g-index

138
all docs

138
docs citations

138
times ranked

4235
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. <i>Blood Reviews</i> , 2019, 36, 70-87. | 5.7 | 484 |
| 2 | Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2191-2197. | 1.6 | 271 |
| 3 | Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. <i>Cancer</i> , 2013, 119, 1257-1265. | 4.1 | 153 |
| 4 | Prevalence of Potentially Inappropriate Medication Use in Older Adults Using the 2012 Beers Criteria. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 486-500. | 2.6 | 127 |
| 5 | A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. <i>Journal of Geriatric Oncology</i> , 2013, 4, 157-165. | 1.0 | 121 |
| 6 | Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. <i>Blood Reviews</i> , 2019, 34, 1-15. | 5.7 | 117 |
| 7 | Medical financial hardship among cancer survivors in the United States. <i>Cancer</i> , 2019, 125, 1737-1747. | 4.1 | 108 |
| 8 | Medical costs and productivity losses of cancer survivors--United States, 2008-2011. <i>Morbidity and Mortality Weekly Report</i> , 2014, 63, 505-10. | 15.1 | 94 |
| 9 | Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. <i>Blood Advances</i> , 2020, 4, 2192-2201. | 5.2 | 68 |
| 10 | Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States. <i>Cancer</i> , 2017, 123, 1453-1463. | 4.1 | 65 |
| 11 | Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. <i>Journal of Clinical Oncology</i> , 2017, 35, 3417-3424. | 1.6 | 61 |
| 12 | Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 175, 829-840. | 2.5 | 59 |
| 13 | Validation of Disability Status, a Claims-based Measure of Functional Status for Cancer Treatment and Outcomes Studies. <i>Medical Care</i> , 2014, 52, 500-510. | 2.4 | 57 |
| 14 | Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. <i>Blood Reviews</i> , 2020, 42, 100706. | 5.7 | 54 |
| 15 | Determinants of Potentially Inappropriate Medication Use among Community-Dwelling Older Adults. <i>Health Services Research</i> , 2017, 52, 1534-1549. | 2.0 | 52 |
| 16 | Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications. <i>Pharmacological Research</i> , 2017, 116, 45-56. | 7.1 | 51 |
| 17 | Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. <i>Cardiovascular Research</i> , 2022, 118, 212-225. | 3.8 | 47 |
| 18 | Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. <i>Blood</i> , 2018, 131, 818-821. | 1.4 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. <i>Cancer</i> , 2016, 122, 1209-1215. | 4.1 | 44 |
| 20 | Changes in Health Insurance Coverage Associated With the Affordable Care Act Among Adults With and Without a Cancer History. <i>Medical Care</i> , 2018, 56, 220-227. | 2.4 | 42 |
| 21 | The Affordable Care Act and Expanded Insurance Eligibility Among Nonelderly Adult Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv181. | 6.3 | 38 |
| 22 | Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3307-3314. | 1.6 | 37 |
| 23 | Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 2245-2253. | 5.2 | 36 |
| 24 | Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3306-3314. | 1.6 | 35 |
| 25 | Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: A single-institution experience. <i>Leukemia Research</i> , 2012, 36, 140-145. | 0.8 | 33 |
| 26 | Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 327-340. | 1.4 | 33 |
| 27 | Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA1-LBA1. | 1.6 | 33 |
| 28 | Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. <i>Blood</i> , 2020, 136, 1946-1955. | 1.4 | 32 |
| 29 | Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. <i>Blood Advances</i> , 2020, 4, 1615-1623. | 5.2 | 32 |
| 30 | Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients. <i>Medical Care</i> , 2009, 47, 1229-1236. | 2.4 | 30 |
| 31 | Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. <i>Leukemia Research</i> , 2013, 37, 675-680. | 0.8 | 30 |
| 32 | Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis. <i>Value in Health</i> , 2016, 19, 631-638. | 0.3 | 30 |
| 33 | Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. <i>Cancer</i> , 2019, 125, 4241-4251. | 4.1 | 28 |
| 34 | Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. <i>Blood Cancer Journal</i> , 2018, 8, 55. | 6.2 | 26 |
| 35 | Cancer History, Health Insurance Coverage, and Cost-Related Medication Nonadherence and Medication Cost-Coping Strategies in the United States. <i>Value in Health</i> , 2019, 22, 762-767. | 0.3 | 26 |
| 36 | Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 3763-3771. | 4.1 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study. <i>Prostate</i> , 2017, 77, 437-445. | 2.3 | 24 |
| 38 | Disease-Related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. <i>Cancer</i> , 2016, 122, 1598-1607. | 4.1 | 19 |
| 39 | Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2020, 61, 397-408. | 1.3 | 19 |
| 40 | Lessons Learned: Who Didn't Enroll In Medicare Drug Coverage In 2006, And Why?. <i>Health Affairs</i> , 2010, 29, 1255-1263. | 5.2 | 18 |
| 41 | Changes in Medication Management After a Diagnosis of Cancer Among Medicare Beneficiaries With Diabetes. <i>Journal of Oncology Practice</i> , 2015, 11, 429-434. | 2.5 | 18 |
| 42 | Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. <i>Cancer</i> , 2017, 123, 3754-3762. | 4.1 | 18 |
| 43 | Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations. <i>JAMA Oncology</i> , 2017, 3, 320. | 7.1 | 18 |
| 44 | Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. <i>JCO Oncology Practice</i> , 2020, 16, e1355-e1370. | 2.9 | 18 |
| 45 | Severe functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 960-968. | 1.0 | 18 |
| 46 | Functional trajectories before and after a new cancer diagnosis among community-dwelling older adults. <i>Journal of Geriatric Oncology</i> , 2019, 10, 60-67. | 1.0 | 17 |
| 47 | Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. <i>Leukemia and Lymphoma</i> , 2017, 58, 982-985. | 1.3 | 16 |
| 48 | Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. <i>Haematologica</i> , 2012, 97, 128-132. | 3.5 | 15 |
| 49 | Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1001-1008. | 4.9 | 15 |
| 50 | Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1178-1187. | 1.3 | 15 |
| 51 | Use and Spending on Antineoplastic Therapy for Medicare Beneficiaries With Cancer. <i>Medical Care</i> , 2013, 51, 351-360. | 2.4 | 13 |
| 52 | Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. <i>Haematologica</i> , 2013, 98, 584-590. | 3.5 | 13 |
| 53 | Patterns of Symptom Management Medication Receipt at End-of-Life Among Medicare Beneficiaries With Lung Cancer. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 767-777.e1. | 1.2 | 13 |
| 54 | Telehealth Availability and Use of Related Technologies Among Medicare-Enrolled Cancer Survivors: Cross-sectional Findings From the Onset of the COVID-19 Pandemic. <i>Journal of Medical Internet Research</i> , 2022, 24, e34616. | 4.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data. <i>Lung Cancer</i> , 2015, 87, 59-64. | 2.0 | 12 |
| 56 | Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. <i>Journal of Oncology Practice</i> , 2017, 13, e505-e515. | 2.5 | 12 |
| 57 | Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. <i>Journal of Clinical Oncology</i> , 2018, 36, 2879-2886. | 1.6 | 12 |
| 58 | Chronic Myelomonocytic Leukemia Is Associated with More Frequent and More Rapid Progression to Acute Myeloid Leukemia and Shorter Survival Than Myelodysplastic Syndrome, but Is Less Frequently Treated: Analysis of Surveillance Epidemiology and End Results Data Linked to Medicare Enrollment Claims. <i>Blood</i> , 2011, 118, 2784-2784. | 1.4 | 12 |
| 59 | Effects of Managed Care on Service Use and Access for Publicly Insured Children With Chronic Health Conditions. <i>Pediatrics</i> , 2007, 119, 956-964. | 2.1 | 10 |
| 60 | Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes. <i>Value in Health</i> , 2012, 15, 404-411. | 0.3 | 10 |
| 61 | Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011. <i>Journal of Geriatric Oncology</i> , 2016, 7, 15-23. | 1.0 | 10 |
| 62 | Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. <i>Cancer</i> , 2019, 125, 4084-4095. | 4.1 | 10 |
| 63 | Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. <i>Cancer</i> , 2018, 124, 4211-4220. | 4.1 | 9 |
| 64 | Patterns of pain medication use associated with reported pain interference in older adults with and without cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 3061-3072. | 2.2 | 9 |
| 65 | Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. <i>PLoS ONE</i> , 2017, 12, e0184747. | 2.5 | 9 |
| 66 | Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. <i>Leukemia Research</i> , 2015, 39, 586-591. | 0.8 | 8 |
| 67 | Low-Income Children With Chronic Conditions Face Increased Costs If Shifted From CHIP To Marketplace Plans. <i>Health Affairs</i> , 2017, 36, 616-625. | 5.2 | 8 |
| 68 | Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use in Myelodysplastic Syndromes. <i>Medicare & Medicaid Research Review</i> , 2014, 4, E1-E16. | 1.3 | 8 |
| 69 | Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. <i>Journal of the National Cancer Institute</i> , 2022, 114, 571-578. | 6.3 | 8 |
| 70 | Use of and spending on supportive care medications among Medicare beneficiaries with cancer. <i>Supportive Care in Cancer</i> , 2014, 22, 2185-2195. | 2.2 | 7 |
| 71 | Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 193-208. | 1.4 | 7 |
| 72 | Impact of sociodemographic characteristics on underemployment in a longitudinal, nationally representative study of cancer survivors: Evidence for the importance of gender and marital status. <i>Journal of Psychosocial Oncology</i> , 2018, 36, 287-303. | 1.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature. <i>Journal of the National Cancer Institute Monographs</i> , 2022, 2022, 12-20. | 2.1 | 7 |
| 74 | A framework for cancer health economics research. <i>Cancer</i> , 2021, 127, 994-996. | 4.1 | 5 |
| 75 | End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. <i>Supportive Care in Cancer</i> , 2021, 29, 3921-3932. | 2.2 | 5 |
| 76 | Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6609-6609. | 1.6 | 5 |
| 77 | Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). <i>Blood</i> , 2015, 126, 873-873. | 1.4 | 5 |
| 78 | Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. <i>Blood Advances</i> , 2022, 6, 376-385. | 5.2 | 5 |
| 79 | Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D. <i>Journal of Oncology Practice</i> , 2015, 11, e190-e198. | 2.5 | 4 |
| 80 | High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D. <i>Journal of Clinical Oncology</i> , 2016, 34, 4307-4309. | 1.6 | 4 |
| 81 | The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2-2. | 1.6 | 4 |
| 82 | Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. <i>Leukemia</i> , 0, , . | 7.2 | 4 |
| 83 | Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. <i>Journal of Palliative Medicine</i> , 2021, 24, 195-204. | 1.1 | 3 |
| 84 | Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8044-8044. | 1.6 | 3 |
| 85 | The adoption of immune checkpoint inhibitors and patterns of care at the end of life.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12027-12027. | 1.6 | 3 |
| 86 | Trends in antineoplastic receipt after medicare payment reform: Implications for future oncology payment design. <i>Journal of Cancer Policy</i> , 2018, 17, 51-58. | 1.4 | 2 |
| 87 | Undertreated pain: Trends over time for older adults with and without cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 15-15. | 1.6 | 2 |
| 88 | Impact of an oncology urgent care clinic on emergency department rates.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6615-6615. | 1.6 | 2 |
| 89 | Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. <i>Blood</i> , 2018, 132, 3580-3580. | 1.4 | 2 |
| 90 | Undertreated emotional distress in older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 165-165. | 1.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Did quality of life for older cancer survivors improve with the turn of the century in the United States?. <i>Journal of Geriatric Oncology</i> , 2021, 12, 102-105. | 1.0 | 1 |
| 92 | Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer, bladder cancer, and melanoma: An electronic health record study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1233-1241. | 1.9 | 1 |
| 93 | Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). <i>Blood</i> , 2019, 134, 4748-4748. | 1.4 | 1 |
| 94 | Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. <i>Blood</i> , 2016, 128, 1188-1188. | 1.4 | 1 |
| 95 | Patterns of palliative symptom management (PSM) medication use at end-of-life (EoL) among Medicare beneficiaries with advanced lung cancer (advLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 130-130. | 1.6 | 1 |
| 96 | The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e24009-e24009. | 1.6 | 1 |
| 97 | Financial hardship associated with cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6608-6608. | 1.6 | 1 |
| 98 | Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). <i>Blood</i> , 2015, 126, 3285-3285. | 1.4 | 1 |
| 99 | Development and evaluation of a proxy for baseline ECOG PS in advanced non-small cell lung cancer (aNSCLC), bladder cancer (aBCa), and melanoma (aMM): An electronic health records (EHR) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18194-e18194. | 1.6 | 1 |
| 100 | Patterns of medication use at end of life by pediatric inpatients with cancer. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28837. | 1.5 | 1 |
| 101 | Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes. <i>Blood</i> , 2020, 136, 2-3. | 1.4 | 1 |
| 102 | Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2020, 136, 21-22. | 1.4 | 1 |
| 103 | Impact of Part D on previously uninsured Medicare beneficiaries with hypertension. <i>Journal of Pharmaceutical Health Services Research</i> , 2012, 3, 141-148. | 0.6 | 0 |
| 104 | Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 853-854. | 1.6 | 0 |
| 105 | Tertiary Center Referral Patterns for Myelodysplastic Syndrome (MDS) Patients Are Suggestive of Age and Race Disparities. <i>Blood</i> , 2010, 116, 1881-1881. | 1.4 | 0 |
| 106 | Sociodemographic and patient disparities in use of first-line chemotherapy (CT) in older adult patients (pts) with advanced non-small cell lung cancer (AdvNSCLC): Analysis of Surveillance, Epidemiology, and End Results (SEER)-Medicare data.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6131-6131. | 1.6 | 0 |
| 107 | How do elderly cancer survivors fare? A comparison of characteristics, health status, health behaviors, and spending between Medicare beneficiaries with and without a cancer history.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6028-6028. | 1.6 | 0 |
| 108 | Out-of-pocket (OOP) health care expenditure burden for Medicare beneficiaries with cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6075-6075. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Did FDA safety warnings and CMS coverage restrictions improve guideline adherence for ESA use for patients with myelodysplastic syndromes?. <i>Journal of Clinical Oncology</i> , 2012, 30, e16519-e16519. | 1.6 | 0 |
| 110 | Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 971-971. | 1.4 | 0 |
| 111 | Short Survival and High Rates of Transformation Prevail in Chronic Myelomonocytic Leukemia Despite Hypomethylating Agent Therapy.. <i>Blood</i> , 2012, 120, 2800-2800. | 1.4 | 0 |
| 112 | Trends in antineoplastic receipt after Medicare payment reform: Implications for future oncology payment design.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6513-6513. | 1.6 | 0 |
| 113 | Impact of health insurance transitions on cancer survivors and those with no cancer history.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6539-6539. | 1.6 | 0 |
| 114 | Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. <i>Blood</i> , 2015, 126, 1676-1676. | 1.4 | 0 |
| 115 | Early impact of the Affordable Care Act (ACA) on financial worry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 44-44. | 1.6 | 0 |
| 116 | The benefit of modern cancer therapy for older patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18141-e18141. | 1.6 | 0 |
| 117 | Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6599-6599. | 1.6 | 0 |
| 118 | Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. <i>Blood</i> , 2016, 128, 394-394. | 1.4 | 0 |
| 119 | Functional trajectories before and after a new cancer diagnosis among community-living older adults.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21547-e21547. | 1.6 | 0 |
| 120 | Physician volume and discontinuation of rituximab during lymphoma treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6593-6593. | 1.6 | 0 |
| 121 | Changes in insurance coverage associated with health care reform for cancer survivors aged 19-64 years.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6527-6527. | 1.6 | 0 |
| 122 | Closure of Medicare Part D coverage gap by the Affordable Care Act (ACA) and use of oral anti-myeloma agents.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6522-6522. | 1.6 | 0 |
| 123 | Effect of a new cancer diagnosis on labor force participation (LFP): Has there been a change over time?. <i>Journal of Clinical Oncology</i> , 2017, 35, e18004-e18004. | 1.6 | 0 |
| 124 | Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7057-7057. | 1.6 | 0 |
| 125 | Cost-related changes in medication use among cancer survivors by socioeconomic status.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18920-e18920. | 1.6 | 0 |
| 126 | Changes in access to care and financial hardship associated with Affordable Care Act (ACA) implementation for cancer survivors aged 19-64 years.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6565-6565. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Cancer survivorship, financial wellbeing and food insecurity in the U.S.. Journal of Clinical Oncology, 2018, 36, 10075-10075. | 1.6 | 0 |
| 128 | Patterns and determinants of pain and emotional distress in older adults with cancer: A population based study.. Journal of Clinical Oncology, 2018, 36, 10105-10105. | 1.6 | 0 |
| 129 | Cancer history, health insurance coverage, and cost-related medication nonadherence and medication cost-coping strategies in the United States.. Journal of Clinical Oncology, 2018, 36, 68-68. | 1.6 | 0 |
| 130 | Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. Blood, 2018, 132, 3538-3538. | 1.4 | 0 |
| 131 | End-of-life (EOL) trajectories among older adults dying with lung cancer (LC).. Journal of Clinical Oncology, 2020, 38, e24008-e24008. | 1.6 | 0 |
| 132 | Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.. Journal of Clinical Oncology, 2020, 38, e19057-e19057. | 1.6 | 0 |
| 133 | The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).. Journal of Clinical Oncology, 2020, 38, e19367-e19367. | 1.6 | 0 |
| 134 | Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. Blood, 2021, 138, 4092-4092. | 1.4 | 0 |
| 135 | Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies.. Journal of Clinical Oncology, 2020, 38, 38-38. | 1.6 | 0 |
| 136 | Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood, 2020, 136, 44-45. | 1.4 | 0 |